Information Provided By:
Fly News Breaks for March 29, 2016
TROV
Mar 29, 2016 | 06:12 EDT
Piper Jaffray analyst William Quirk says he always viewed Dr. Schuh as a visionary CEO with limited experience launching new products. He suspects the firing of the CEO and CFO will allow those with commercialization experience within Trovagene to now play a bigger role. Quirk believes this is a positive for the company's longer-term product commercialization, but admits the stock is likely to be down today significantly following last night's news. The analyst has an Overweight rating on Trovagene with an $8 price target.
News For TROV From the Last 2 Days
There are no results for your query TROV
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.